Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 13/20 | 0.63 |
| ▸ | NPC1 | O15118 | 6/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | CLK1 | P49759 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3396058 | 0.75 | NPC1 (0.62) | APPNPC1RAB9APAX8KDM4E | |
| SCHEMBL1691324 | 0.74 | GABRA1 (0.41) | NPC1RAB9AKDM4EGAAHPGD | |
| SCHEMBL16594120 | 0.74 | KMT2A (0.42) | NPC1RAB9AKDM4EALDH1A1POLB | |
| Trifluoroacetic Acid SCHEMBL2128124 | 0.73 | APP (0.58) | APPNPC1RAB9APAX8KDM4E | |
| SCHEMBL7605200 | 0.73 | NPC1 (0.77) | APPNPC1RAB9APAX8KDM4E | |
| SCHEMBL5048521 | 0.72 | APP (1.00) | APPNPC1RAB9APAX8 | |
| SCHEMBL973527 | 0.72 | NPC1 (1.00) | APPNPC1RAB9APAX8KDM4E | |
| Bromide SCHEMBL1691457 | 0.71 | NPC1 (0.75) | APPNPC1RAB9APAX8KDM4E | |
| SCHEMBL19322147 | 0.70 | NPC1 (0.74) | APPNPC1RAB9APAX8KDM4E | |
| SCHEMBL22123558 | 0.70 | MLLT1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150239905-A1 | IMIDAZOPYRIDINE COMPOUNDS | BIOVITRUM AB (PUBL) (SE) | 2015-08-27 | — | — | US | disclosed |
| US-20140206662-A1 | Imidazopyridine Compounds | PROXIMAGEN LTD. (GB) | 2014-07-24 | — | — | US | disclosed |
| US-20120010188-A1 | Imidazopyridine Compounds | PROMIMAGEN LTD. (GB) | 2012-01-12 | — | — | US | disclosed |
| EP-2376490-A1 | IMIDAZOPYRIDINE COMPOUNDS | Proximagen Limited (GB) | 2011-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010188-A1 | Imidazopyridine Compounds | SSB, MIF, IDO1 | APP 2459/4885NPC1 1153/4885RAB9A 3798/4885 |
| US-20150239905-A1 | IMIDAZOPYRIDINE COMPOUNDS | SSB, MIF, IDO1 | APP 2459/4885NPC1 1153/4885RAB9A 3798/4885 |
| US-20140206662-A1 | Imidazopyridine Compounds | SSB, NFKBIA, TPMT | APP 2152/4885NPC1 2286/4885RAB9A 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.